A pharmaceutical composition, comprising effective amounts of: (i) (A compound 1 of formula (I): ** Formula ** wherein the abbreviations X1, X2, X3, X4 and X5 used in the Table mean in each case a binding to the position in the general formula shown in the Table instead of the corresponding groups R1, R2, R3, R4 and L-R5, optionally in the form of their tautomers, racemates, enantiomers, diastereomers and mixtures thereof and optionally in the form of the pharmacologically acceptable acid, solvate, hydrate or polymorphic addition salts thereof； and (ii) at least one additional therapeutic agent 2 selected from the group consisting of vatalanib, gefitinib, erlotinib, iressa, tarceva, herceptin, atrasentan, rituximab, cetuximab, Avastin tm (bevacizumab), IMC-1C11, erbitux (C-225), DC-101, EMD-72000, vitaxin, imatinib, VEGFtrap, melphalan, cyclophosphamide, an oxazaphosphine, doxorubicamine (docloorubicamine) adriamycin), doxorubic ina liposomal (doxil), epirubicin, idarubicin, mitoxantrone, amsacrine, dactinomycin, distamycin, netropsin, pibenzimol, mitomycin, CC-1065, duocarmycin, mitramycin, chromomycin, olivomycin, propamidine, stilbamidine, an antramycin, an antramreacin phleomycin a bleomycin, liblomicina, navelbine, vinblastine, vincristine, vindesine, vinorelbine, colchicine, maytansine, fomopsina, dolastatin, etoposide, teniposide, combretastatin, anfetinilo, procarbazine, bortezomib, asparaginase, pegylated asparaginase (pegaspargase), inhibitor timidinafosforilasa, estramustine (T-66), megestrol, flutamide, casodex, anandron, cyproterone acetate, aminoglutethimide, anastrozole, formestan, letrozole, leuprorelin, buserelin, goserelin or triptorelin, tamoxifen, droloxifene, trioxifene, raloxifenoid, zindoxadiene, zindoxadiene, zindoxadiene, zindoxadiene finasteride, ketoconazole, leuprolide, prednisone, prednisolone, methylprednisolone, dexamethasone, budenoside, fluoc ortholone or triamcinolone, interferon, interferon β, IL-10, IL-12, etanercept, thalidomide,
